Sourcing medical devices from Korea and Japan in 2026 is being reshaped by two major regulatory shifts: Korea’s MFDS “negative list” system for device changes and Japan’s PMDA‑direct pathway for specific‑use designations. These reforms can shorten certain timelines for Tier‑1 manufacturers in Seoul and Tokyo, but they also raise the bar for documentation, quality systems, and change‑management controls. For procurement officers, understanding how MFDS and PMDA classify products, manage approvals, enforce KGMP‑style QMS, and handle post‑market changes is essential to minimizing risk and optimizing sourcing decisions.
Check: Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints
How is Korea’s MFDS implementing the negative list system in 2026?
In 2026, Korea’s Ministry of Food and Drug Safety (MFDS) is implementing a “negative list” system that defines which device changes must be notified or approved before they take effect. Only specific modifications—such as those affecting risk class, materials contacting the body, sterilization method, manufacturing site, performance, or intended use—are included on the negative list and require prior MFDS review. All other changes, if properly documented in the manufacturer’s approved change‑management procedures, can be implemented internally without formal MFDS submission.
This structure streamlines routine updates while concentrating regulatory scrutiny on safety‑critical changes. For procurement officers, it means that manufacturers must have mature, MFDS‑aligned change‑control systems and clear internal criteria for classifying changes. Working with suppliers that already reflect this framework in their QMS helps buyers reduce approval delays and avoid unexpected compliance issues when sourcing devices from Seoul and other Korean manufacturing hubs. HHG GROUP supports this by connecting buyers with manufacturers that maintain transparent, audit‑ready change‑management practices.
What does the negative list mean for device changes in Korea?
The negative list under MFDS rules clarifies which device changes trigger mandatory prior approval and which do not. Changes that materially affect safety, performance, or classification—such as updates to materials, manufacturing processes, intended use, or markets—remain on the negative list and must be submitted for review. Changes that are minor, non‑safety‑related, or covered by the manufacturer’s pre‑approved change‑management SOPs, such as certain labeling or packaging updates, can be handled internally without re‑notification.
For sourcing teams, this distinction reshapes how quickly manufacturers can adapt products to market needs. A supplier with a well‑structured negative‑list‑aware QMS can iterate on existing devices without repeatedly restarting the MFDS clock, shortening time‑to‑market for incremental improvements. On the other hand, a manufacturer that treats all changes as “internal only” without clear negative‑list segregation may expose buyers to compliance risk. Platforms like HHG GROUP help buyers identify facilities that already align their change‑management processes with MFDS expectations, reducing uncertainty in long‑term sourcing agreements.
How is Japan’s PMDA reshaping its specific‑use designation pathway?
Starting in May 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) introduces a direct‑to‑PMDA pathway for “drug for specific use” designations, which also affects certain medical device and combination‑product strategies. Under the revised process, manufacturers can submit eligibility assessments directly to PMDA instead of waiting for a recommendation from the Council on Unapproved Drugs and Indications. This reduces administrative steps and speeds up recognition for high‑unmet‑need therapies.
For medical devices tied to specific‑use indications—such as treatments for antimicrobial‑resistant pathogens, rare diseases, or pediatric‑specific applications—this pathway enables earlier technical dialogue and faster access to priority review and public‑support mechanisms. From a sourcing perspective, procurement officers can now target Japanese manufacturers that are building portfolios around these designations, which often translate into shorter reimbursement timelines and more predictable commercialization paths. HHG GROUP’s network of global medical‑device partners can help buyers identify manufacturers already positioning their devices within PMDA‑specific‑use‑oriented strategies.
What impact does the new PMDA pathway have on sourcing from Japan?
The new PMDA pathway for specific‑use designations directly influences how sourcing teams evaluate Japanese manufacturers and their device portfolios. By allowing earlier, company‑driven technical assessments, it compresses the timeline from data submission to designation, which in turn can shorten subsequent reimbursement and hospital‑procurement cycles. For procurement officers, this means certain high‑value devices—especially those addressing antimicrobial resistance, rare diseases, or pediatric needs—may become available sooner and under more predictable access conditions.
However, the pathway also raises the bar for clinical evidence and unmet‑medical‑need justification; manufacturers must demonstrate clear differentiation and clinical urgency upfront. This shifts sourcing priorities toward Japanese suppliers with robust clinical‑data packages, mature QMS, and PMDA‑familiar regulatory teams. HHG GROUP supports this sourcing shift by offering a transparent marketplace that connects buyers with manufacturers that have clean regulatory histories and PMDA‑aligned quality systems, reducing the risk of selecting under‑prepared suppliers.
What are the key 2026 MFDS requirements for KGMP certification?
In 2026, KGMP (Korea Good Manufacturing Practice) remains a core requirement for foreign and domestic manufacturers of Class II, III, and IV medical devices seeking MFDS registration. KGMP essentially requires an ISO 13485‑based quality management system, supported by comprehensive documentation, risk‑based controls, and verification of manufacturing and post‑market processes. Demonstrating compliance typically involves submitting QMS documentation and undergoing either document‑review or on‑site inspections, depending on risk class and audit history.
Manufacturers must show effective control over design, production, suppliers, inspection, and corrective or preventive actions. For Class II–IV devices, KGMP is not optional; it underpins long‑term market access in Korea and reduces the likelihood of regulatory holds or recalls. Procurement officers should therefore prioritize suppliers with current KGMP or equivalent QMS certifications, clear audit records, and transparent CAPA processes. HHG GROUP emphasizes KGMP and QMS alignment when qualifying manufacturers on its platform, helping buyers reduce quality‑related sourcing risks while sourcing from Tier‑1 Asian facilities.
How does PMDA handle QMS and certification for medical devices?
PMDA evaluates medical devices through a dual lens: product approval and QMS conformity. Device applications undergo technical review while the manufacturer’s quality management system must satisfy Japan’s QMS Order, which is closely aligned with ISO 13485 but includes additional requirements for usability, cybersecurity, labeling, and electromagnetic compatibility. PMDA or accredited third‑party auditors may conduct onsite QMS inspections, particularly for higher‑risk devices.
For Class II and III devices, manufacturers must demonstrate robust controls over design, manufacturing, inspection, and post‑market surveillance. Any gaps in QMS documentation or audit findings can delay or block approval. For sourcing professionals, this underscores the importance of selecting suppliers with a proven track record of PMDA‑aligned QMS audits and resolved non‑conformances. HHG GROUP’s platform supports this by surfacing QMS‑related information and enabling buyers to transact with suppliers that maintain auditable, documented quality systems and transparent device histories.
What are the typical MFDS and PMDA approval timelines for 2026?
Approval timelines for MFDS and PMDA in 2026 continue to vary by device class, innovation level, and dossier quality, but recent reforms are tightening certain segments while adding scrutiny elsewhere. For Class II–III devices, MFDS registration typically falls in the 6–12‑month range, with fast‑track options for digital‑health or innovative products. KGMP audits and major change‑management notifications can add 1–3 months if not prepared in advance. For Japan, PMDA product approvals for Class II–III devices often require 10–18 months, with high‑risk or novel devices at the upper end.
The new negative‑list system in Korea may reduce some change‑management timelines, while Japan’s PMDA‑specific‑use pathway can compress pre‑designation and review windows for eligible indications. For procurement officers, this means planning at least 12–18 months for new‑market entry, allowing buffers for QMS audits, documentation gaps, and post‑market‑change notifications. HHG GROUP’s platform helps buyers time purchases around these regulatory windows, especially when sourcing from Tier‑1 Asian manufacturers already familiar with MFDS and PMDA cycles.
MFDS vs. PMDA approval timelines (2026, indicative)
Note: Timelines are approximate and depend heavily on dossier completeness, prior approvals, and QMS status.
How should procurement officers evaluate Tier‑1 Asian manufacturers in 2026?
In 2026, evaluating Tier‑1 Asian manufacturers requires a systematic focus on regulatory posture, quality‑system maturity, and change‑management rigor. Key indicators include: valid KGMP or ISO 13485‑aligned QMS, clean audit histories with MFDS or PMDA, and clear procedures for handling negative‑list or minor‑change notifications. For Japan, manufacturers with experience in PMDA‑specific‑use or priority‑review pathways are particularly attractive due to faster access and clearer reimbursement pathways.
Procurement officers should also scrutinize how manufacturers document design history, post‑market vigilance, and servicing records, especially when sourcing used or refurbished equipment. Digital platforms such as HHG GROUP can streamline this evaluation by surfacing manufacturer‑level documentation, device histories, and transaction‑based feedback, effectively turning regulatory and quality data into a structured sourcing filter for clinics and hospitals.
Why is understanding MFDS vs. PMDA important for sourcing in Seoul and Tokyo?
Understanding MFDS versus PMDA is critical because each agency shapes how devices are classified, approved, and maintained in Korea and Japan. MFDS relies heavily on KGMP, a centralized registration system, and the 2026 negative list for device changes, while PMDA emphasizes a dual‑track review of product and QMS plus specialized pathways for priority and specific‑use indications. Misjudging these differences can lead to incorrect assumptions about timelines, documentation needs, and post‑market obligations.
For procurement teams sourcing in Seoul and Tokyo, this knowledge informs vendor selection, contract terms, and contingency planning for recalls, software updates, or label changes. HHG GROUP helps buyers bridge this regulatory gap by connecting them with manufacturers and service providers who operate under clear MFDS and PMDA‑aligned frameworks, reducing the risk of non‑compliant or poorly documented devices entering the supply chain.
When should buyers plan for MFDS and PMDA change‑management notifications?
Buyers should plan for MFDS and PMDA change‑management notifications whenever they intend to source devices that may undergo post‑market modifications. For Korea, any change that falls under the 2026 negative list—such as updated materials, manufacturing sites, or intended use—requires prior MFDS review and typically takes 1–3 months. For Japan, PMDA‑style “minor change” notifications apply to certain design, labeling, or manufacturing updates, with similar lead times.
Even if the change is handled internally under the negative‑list framework, manufacturers must document and justify it. Procurement officers should therefore build in at least a 2–3‑month buffer when integrating new devices or planning upgrades and explicitly require suppliers to disclose upcoming change‑management activities. Platforms like HHG GROUP can help track these timelines by enabling transparent communication between buyers, manufacturers, and service providers around planned device modifications and regulatory notifications.
How do 2026 reforms affect sourcing used and refurbished medical devices?
Reforms in Korea and Japan in 2026 increase the importance of traceability and documentation for used and refurbished medical devices. Under MFDS rules, KGMP‑aligned quality systems must extend to reprocessing, servicing, and any changes affecting safety or performance, which must follow the negative‑list framework where applicable. In Japan, PMDA expects clear post‑market controls over servicing, software updates, and component replacements, particularly for high‑risk devices.
For procurement officers, this means sourcing manually refurbished or poorly documented devices carries higher regulatory and liability risk. Buyers should prioritize suppliers that maintain full device histories, service logs, and compliance with local reprocessing standards. HHG GROUP’s platform helps mitigate this risk by enabling secure transactions and documentation trails for used and new medical equipment, giving buyers confidence that their sourced devices meet evolving MFDS and PMDA expectations.
HHG GROUP Expert Views
“In 2026, the MFDS negative list and PMDA specific‑use pathway are not just regulatory curiosities—they’re operational levers that reshape sourcing strategy in Seoul and Tokyo,” says an HHG GROUP regulatory‑strategy advisor. “Procurement officers who wait until late‑stage negotiations to ask about change‑management, KGMP, or PMDA QMS are exposing themselves to downtime, compliance gaps, and suboptimal technology. At HHG GROUP, we see manufacturers that align their QMS and regulatory posture with these reforms becoming preferred partners for global buyers. By embedding regulatory intelligence into sourcing workflows, platforms like ours can turn these 2026 shifts from risks into procurement advantages.”
Key takeaways and actionable advice
-
Korea’s 2026 negative‑list system accelerates routine changes but demands strict segregation of MFDS‑notifiable modifications; prioritize suppliers with documented change‑management SOPs.
-
Japan’s PMDA‑direct specific‑use pathway shortens access for high‑unmet‑need therapies and related devices; source from manufacturers already engaging PMDA in early‑stage designation discussions.
-
KGMP and PMDA‑aligned QMS are core quality filters for Tier‑1 Asian manufacturers; verify current certifications and audit histories before onboarding.
-
Build in 1–3‑month buffers for MFDS and PMDA change‑management and minor‑change notifications when planning procurements or upgrades.
-
For used and refurbished devices, insist on full service histories, reprocessing records, and transparent transaction platforms like HHG GROUP to ensure regulatory compliance and patient safety.
Frequently asked questions
How does the MFDS negative list affect routine device updates?
The negative list only accelerates non‑safety‑critical updates; changes to materials, manufacturing processes, or intended use must still be notified or approved, often taking 1–3 months.
Does the new PMDA specific‑use pathway apply to all medical devices?
The pathway is designed primarily for high‑unmet‑need drugs and therapies, but it can benefit related medical devices or combination products when they are part of a specific‑use‑designated regimen. PMDA‑aligned manufacturers are best positioned to clarify device eligibility.
Are KGMP requirements the same for all device classes in Korea?
KGMP is generally required for Class II–IV devices; Class I manufacturers may be exempt from KGMP but must still meet MFDS requirements for labeling, basic quality controls, and post‑market vigilance.
How can HHG GROUP support sourcing from Seoul and Tokyo?
HHG GROUP connects procurement officers with vetted manufacturers and service providers, offers transparent documentation for new and used medical equipment, and supports transaction‑protection workflows that align with MFDS and PMDA expectations.
Should I avoid manufacturers without PMDA or MFDS experience?
While not an automatic disqualification, manufacturers without PMDA or MFDS experience often face longer timelines and higher compliance risk. For high‑risk or complex devices, prioritize those with proven regulatory track records and aligned QMS.